Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2003
10/22/2003CN1451004A 7-oxo pyridopyrimidines
10/22/2003CN1450999A Novel piperazine derivatives
10/22/2003CN1450996A 2-guanidino-4-aryl-quinazoline
10/22/2003CN1450923A Method and compositions for administering taxanes orally to human patients
10/22/2003CN1450907A Beta glycan as an inhibin receptor and uses thereof
10/22/2003CN1450894A Phenylethylamines and condensed rings variants as prodrugs of catecholamines and their use
10/22/2003CN1450891A Formulation based on heparin, glycosaminogl ycan or heparinoid, use of the formulation and the formulation base
10/22/2003CN1449777A Medicine for treating kidney disease
10/22/2003CN1124851C Chinese patent medicine for treating diabetes and nephrosis and its preparing process
10/22/2003CN1124848C Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
10/21/2003US6635786 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
10/21/2003US6635776 Lipoxin compounds and their use in treating cell proliferative disorders
10/21/2003US6635764 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc.
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635669 Kinase inhibitor; benign prostatic hyperplasia
10/21/2003US6635658 Amino-tetralin derivatives as muscarinic receptor antagonists
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635619 Amino acid sequence 88, 96, 97, 98, 99 or 100; increasing serum and tissue levels of active component
10/21/2003US6635451 Conversion of dihomo-gamma linolenic acid (DGLA) to arachidonic acid and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA); Delta 6 desaturase and Delta 5 desaturase
10/21/2003US6635431 Recombinant lipolysis stimulated (LSR) comprising polypeptide of given sequence; use for selecting a compound for enhancing lipoprotein uptake in cells expressing the polypeptide
10/21/2003US6635288 Pulverizing in solvent; therapy for liver disorders
10/21/2003US6635273 Methods of treating vascular diseases characterized by nitric oxide insufficiency
10/21/2003US6635270 NMDA receptor agonist pharmaceutical compositions
10/21/2003CA2240136C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
10/21/2003CA2213737C 2-arylbenzazole compounds
10/21/2003CA2037884C Stabilized gonadotropin containing preparations
10/16/2003WO2003084966A1 Oxazolidinone derivatives
10/16/2003WO2003084961A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003WO2003084956A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
10/16/2003WO2003084955A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084951A1 (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
10/16/2003WO2003084943A2 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003WO2003084941A2 Hydroxamic acid derivatives
10/16/2003WO2003084940A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003WO2003084934A1 Novel crystal form of 5-hydroxy-1-methylhydantoin
10/16/2003WO2003084928A1 Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
10/16/2003WO2003084917A1 (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
10/16/2003WO2003084555A1 Compositions for inhibiting fibrosis
10/16/2003WO2003084549A1 Hormone replacement therapy
10/16/2003WO2003084541A1 Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003062276A3 Multimers of receptor-binding ligands
10/16/2003WO2003059282A3 Human monoclonal antibodies against cd30
10/16/2003WO2003051393A3 Enzymatic cleavable reagents for specific delivery to disease sites
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
10/16/2003WO2003037314A3 Medical compositions for intravesical treatment of bladder cancer
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003033527A3 Cyclosporine analogue mixtures and their use as immunomodulating agents
10/16/2003WO2003032969B1 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
10/16/2003WO2003024993A3 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
10/16/2003WO2003015494A3 Tocopherol enriched compositions and amelioration of inflammatory symptoms
10/16/2003WO2003011314A3 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
10/16/2003WO2003011211A3 Peg-modified uricase
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002085299A3 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/16/2003WO2002084298A3 Medicaments which are modulators of hm74 and/or hm74a activity
10/16/2003WO2002036151A3 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
10/16/2003US20030196217 Desaturase genes, enzymes encoded thereby, and uses thereof
10/16/2003US20030195352 For therapy of diabetes, obesity, impaired glucose tolerance, gastrointestinal disorders, hypertriglyceridemia, hypercholesteolemia, atherosclerotic disorders, or cardiovascular disorders
10/16/2003US20030195247 Antagonists of protein tryosin phosphatase 1B (PTP-1B) and T-cell protein tyrosine phosphatase (TC-PTP), used as antidiabetic agents and for prophylaxis of insulin resistance
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195235 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/16/2003US20030195215 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors
10/16/2003US20030195214 Cancer treatment
10/16/2003US20030195211 Inhibitors of human phosphatidylinositol 3-kinase delta
10/16/2003US20030195210 An enzyme inhibitors of cyclic guanosine 3',5'-monophophate-metabolizing phosphodiesterases; treating cardiovascular disorders, brian disorders, Alzheimer's disease, urogenital or sexual disorders
10/16/2003US20030195201 Vanilloid receptor ligands and their use in treatments
10/16/2003US20030195194 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195172 Novel phosphonic acid compounds as inhibitors of serine proteases
10/16/2003US20030195171 Method for inhibiting bone resorption with an alendronate and vitamin D formulation
10/16/2003US20030195169 Such as (S)-phosphoric acid mono-(3-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxso-6-trifluoromethyl-2,3 -dihydro-indol-1-ylmethyl)ester; for modulation of large-conductance calcium-activated potassium (BK) channels
10/16/2003US20030195157 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
10/16/2003US20030194720 Human ion channels
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481888A1 Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481035A1 (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2462708A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/15/2003EP1352897A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352896A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352895A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352651A2 Novel use of orexin receptor antagonists
10/15/2003EP1352073A2 Electrically responsive promoter system
10/15/2003EP1352063A2 Receptor nucleic acids and polypeptides
10/15/2003EP1352062A2 Improved growth hormone molecules
10/15/2003EP1351980A2 Peptides for activation and inhibition of delta pkc
10/15/2003EP1351975A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
10/15/2003EP1351962A2 Thienopyrimidine
10/15/2003EP1351961A1 Substituted indolines as 5-ht receptor ligands
1 ... 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 ... 562